ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Business Roundup

June 30, 2014 | APPEARED IN VOLUME 92, ISSUE 26

Altana has invested $135 million in Israel’s Landa Digital Printing, which is developing a water-based digital printing process called

BioAmber has secured a $20 million loan that it will use to complete the construction of its biobased succinic acid plant in Sarnia, Ontario. The company says the 30,000-metric-ton-per-year facility will be the world’s largest such plant when it opens in early 2015.

Sigma-Aldrich Fine Chemicals will join with Applied Genetic Technologies, a developer of eye disease therapies, to provide gene therapy manufacturing services. AGT will help engineer adeno-associated virus-based vectors for customers. SAFC will manufacture the vectors using AGT’s HAVE technology.

H.B. Fuller will spend about $230 million to acquire Tonsan Adhesive, which calls itself China’s largest independent engineering adhesives provider. Tonsan has about $100 million in annual sales of silicone, epoxy, anaerobic, and cyanoacrylate adhesives.

Spectris, a British maker of instruments and controls, has acquired Claisse, a Canadian provider of sample preparation equipment for atomic spectroscopy. Claisse, which has annual sales of about $13 million, will become part of Spectris’s PANalytical business.

Roche will use nanomedicine technology called Accurins from Bind Therapeutics in areas outside oncology. Accurins are polymeric nanoparticles designed to keep a therapeutic payload circulating within the bloodstream. Cambridge, Mass.-based Bind already has deals with Amgen, Astra­Zeneca, and Pfizer.

Alexion Pharmaceuticals and Cincinnati Children’s Hospital Medical Center have formed a partnership under which Alexion will back rare-disease-related research programs at the hospital in exchange for rights to license them. The medical center will receive milestone payments and royalties on any resulting products.

Numerate, a San Bruno, Calif.-based biotech firm, has raised $8 million in a funding round led by Atlas Venture and Lilly Ventures. Numerate is applying machine-learning algorithms to small-molecule drug discovery.

Advertisement
X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment